Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

After decades, scientists have finally pieced together the 23-step biosynthetic pathway to produce this cancer drug ...

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult ...

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...

Optune Pax is a portable medical device that delivers TTFields non-invasively via wearable arrays to disrupt electrical processes essential for cancer cell division.

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ ...

The combination is the first immune checkpoint inhibitor-based regimen to show a survival benefit for patients with ...

Median overall survival (OS) and progression-free survival (PFS) in uterine carcinosarcoma (UCS) both improved with paclitaxel and carboplatin as compared with a standard-of-care regimen, a randomized ...

Molecular comparison between peritoneal metastases (PM) and primary gastric (GC) and gastroesophageal junction (GEJ) cancer. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This ...

Please provide your email address to receive an email when new articles are posted on . The addition of carboplatin to paclitaxel improved pathologic complete response and EFS with no increase in ...

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial Intermittent relacorilant + ...